221 related articles for article (PubMed ID: 14657536)
1. Small-molecule epidermal growth factor receptor tyrosine kinase inhibitors.
Janmaat ML; Giaccone G
Oncologist; 2003; 8(6):576-86. PubMed ID: 14657536
[TBL] [Abstract][Full Text] [Related]
2. Biologically targeted treatment of non-small-cell lung cancer: focus on epidermal growth factor receptor.
Natale RB
Clin Lung Cancer; 2003 Sep; 5 Suppl 1():S11-7. PubMed ID: 14641989
[TBL] [Abstract][Full Text] [Related]
3. Targeting the epidermal growth factor receptor.
El-Rayes BF; LoRusso PM
Br J Cancer; 2004 Aug; 91(3):418-24. PubMed ID: 15238978
[TBL] [Abstract][Full Text] [Related]
4. The impact of gefitinib on epidermal growth factor receptor signaling pathways in cancer.
Averbuch SD
Clin Lung Cancer; 2003 Sep; 5 Suppl 1():S5-S10. PubMed ID: 14641988
[TBL] [Abstract][Full Text] [Related]
5. Tyrosine kinase inhibitors-ZD1839 (Iressa).
Arteaga CL; Johnson DH
Curr Opin Oncol; 2001 Nov; 13(6):491-8. PubMed ID: 11673690
[TBL] [Abstract][Full Text] [Related]
6. Epidermal growth factor receptor inhibitors: a new prospective in the treatment of lung cancer.
Tiseo M; Loprevite M; Ardizzoni A
Curr Med Chem Anticancer Agents; 2004 Mar; 4(2):139-48. PubMed ID: 15032719
[TBL] [Abstract][Full Text] [Related]
7. [Epidermal growth factor receptors (EGFR): a new target for anticancer therapy].
Gainet M; Guardiola E; Dufresne A; Pivot X
Cancer Radiother; 2003 Jun; 7(3):195-9. PubMed ID: 12834777
[TBL] [Abstract][Full Text] [Related]
8. HER1/EGFR targeting: refining the strategy.
Pérez-Soler R
Oncologist; 2004; 9(1):58-67. PubMed ID: 14755015
[TBL] [Abstract][Full Text] [Related]
9. EGFR blockade by tyrosine kinase inhibitor or monoclonal antibody inhibits growth, directs terminal differentiation and induces apoptosis in the human squamous cell carcinoma HN5.
Modjtahedi H; Affleck K; Stubberfield C; Dean C
Int J Oncol; 1998 Aug; 13(2):335-42. PubMed ID: 9664130
[TBL] [Abstract][Full Text] [Related]
10. Development of the epidermal growth factor receptor inhibitor OSI-774.
Grünwald V; Hidalgo M
Semin Oncol; 2003 Jun; 30(3 Suppl 6):23-31. PubMed ID: 12802792
[TBL] [Abstract][Full Text] [Related]
11. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
[TBL] [Abstract][Full Text] [Related]
12. Is there a role for epidermal growth factor receptor inhibitors in breast cancer prevention?
Konecny GE; Wilson CA; Slamon DJ
J Natl Cancer Inst; 2003 Dec; 95(24):1813-5. PubMed ID: 14679144
[No Abstract] [Full Text] [Related]
13. Epidermal growth factor receptor targeting in cancer: a review of trends and strategies.
Yewale C; Baradia D; Vhora I; Patil S; Misra A
Biomaterials; 2013 Nov; 34(34):8690-707. PubMed ID: 23953842
[TBL] [Abstract][Full Text] [Related]
14. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.
Takeda M; Okamoto I; Tsurutani J; Oiso N; Kawada A; Nakagawa K
Jpn J Clin Oncol; 2012 Jun; 42(6):528-33. PubMed ID: 22457323
[TBL] [Abstract][Full Text] [Related]
15. EGFR tyrosine kinases inhibitors in cancer treatment: in vitro and in vivo evidence.
Quatrale AE; Porcelli L; Silvestris N; Colucci G; Angelo A; Azzariti A
Front Biosci (Landmark Ed); 2011 Jan; 16(5):1962-72. PubMed ID: 21196276
[TBL] [Abstract][Full Text] [Related]
16. Epidermal growth factor receptor inhibition strategies in oncology.
Harari PM
Endocr Relat Cancer; 2004 Dec; 11(4):689-708. PubMed ID: 15613446
[TBL] [Abstract][Full Text] [Related]
17. Developing inhibitors of the epidermal growth factor receptor for cancer treatment.
Grünwald V; Hidalgo M
J Natl Cancer Inst; 2003 Jun; 95(12):851-67. PubMed ID: 12813169
[TBL] [Abstract][Full Text] [Related]
18. Distribution and function of EGFR in human tissue and the effect of EGFR tyrosine kinase inhibition.
Yano S; Kondo K; Yamaguchi M; Richmond G; Hutchison M; Wakeling A; Averbuch S; Wadsworth P
Anticancer Res; 2003; 23(5A):3639-50. PubMed ID: 14666659
[TBL] [Abstract][Full Text] [Related]
19. An update of the mechanisms of resistance to EGFR-tyrosine kinase inhibitors in breast cancer: Gefitinib (Iressa) -induced changes in the expression and nucleo-cytoplasmic trafficking of HER-ligands (Review).
Ferrer-Soler L; Vazquez-Martin A; Brunet J; Menendez JA; De Llorens R; Colomer R
Int J Mol Med; 2007 Jul; 20(1):3-10. PubMed ID: 17549382
[TBL] [Abstract][Full Text] [Related]
20. Emerging treatments in oncology: focus on tyrosine kinase (erbB) receptor inhibitors.
Hamid O
J Am Pharm Assoc (2003); 2004; 44(1):52-8. PubMed ID: 14965154
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
